UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000010049
Receipt No. R000011767
Scientific Title EGF family receptors regulated immunoescape from NK cell-mediated innnate immunity in malignant mesothelioma
Date of disclosure of the study information 2013/04/01
Last modified on 2017/03/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title EGF family receptors regulated immunoescape from NK cell-mediated innnate immunity in malignant mesothelioma
Acronym EGF family receptors regulated immunoescape in malignant mesothelioma
Scientific Title EGF family receptors regulated immunoescape from NK cell-mediated innnate immunity in malignant mesothelioma
Scientific Title:Acronym EGF family receptors regulated immunoescape in malignant mesothelioma
Region
Japan

Condition
Condition malignant mesothelioma
Classification by specialty
Chest surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To assess EGF family signaling induced immunoescape from NK cell-mediated cytotoxicity in malignant mesothelioma
Basic objectives2 Others
Basic objectives -Others Immunological assessment
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes Effects of EGF family signaling on NK cell-mediated cytotoxicity in malignant mesothelioma
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients with malignant mesothelioma who receive surgical treatment or pleural drainage in our institute
Key exclusion criteria none
Target sample size 5

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Riki Okita
Organization Kawasaki Medical School
Division name General Thoracic Surgery
Zip code
Address Matsushima 577, Kurashiki
TEL 086-462-1111
Email riki0716okita@yahoo.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name Riki Okita
Organization Kawasaki Medical School
Division name General Thoracic Surgery
Zip code
Address Matsushima 577, Kurashiki
TEL 086-464-1124
Homepage URL
Email gts@med.kawasaki-m.ac.jp

Sponsor
Institute General Thoracic Surgery, Kawasaki Medical School
Institute
Department

Funding Source
Organization Kawasaki Medical School
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 川崎医科大学附属病院

Other administrative information
Date of disclosure of the study information
2013 Year 04 Month 01 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications https://www.spandidos-publications.com/or/34/6/2864
Number of participants that the trial has enrolled
Results
Okita R, et al. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells. Oncol Rep 2015.
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2013 Year 02 Month 15 Day
Date of IRB
Anticipated trial start date
2013 Year 04 Month 01 Day
Last follow-up date
2019 Year 03 Month 06 Day
Date of closure to data entry
2019 Year 03 Month 06 Day
Date trial data considered complete
2019 Year 03 Month 06 Day
Date analysis concluded
2019 Year 03 Month 06 Day

Other
Other related information case control, prospective study

Management information
Registered date
2013 Year 02 Month 15 Day
Last modified on
2017 Year 03 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011767

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.